Fermented Soy Paste Alleviates Lipid Accumulation in The Liver by Regulating the AMPK Pathway and Modulating Gut Microbiota in High-Fat Diet-Fed Rats.
暂无分享,去创建一个
K. Cheng | Y. Tung | M. Pan | Y. Kuo | T. Lu | Chitang Ho | Yen-Chen Chang | Zhi-Rong Liang | S. Chou | Chi-Tang Ho | Kuan-Chen Cheng
[1] S. Satapathy,et al. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. , 2019, Journal of clinical and experimental hepatology.
[2] V. Wong,et al. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. , 2019, Journal of clinical and experimental hepatology.
[3] Shelly C. Lu,et al. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease , 2019, World journal of gastroenterology.
[4] C. Mantzoros,et al. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.
[5] T. Tsuduki,et al. Miso (Fermented Soybean Paste) Suppresses Visceral Fat Accumulation in Mice, Especially in Combination with Exercise , 2019, Nutrients.
[6] Fumihiko Takeuchi,et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka , 2018, Hepatology International.
[7] J. Lykkesfeldt,et al. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease , 2018, Cellular and Molecular Life Sciences.
[8] H. Xie,et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[9] J. Duan,et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota , 2018, Scientific Reports.
[10] W. Holzapfel,et al. Long-term fermented soybean paste improves metabolic parameters associated with non-alcoholic fatty liver disease and insulin resistance in high-fat diet-induced obese mice. , 2018, Biochemical and biophysical research communications.
[11] V. Patel,et al. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease , 2018, Alimentary pharmacology & therapeutics.
[12] A. Sahebkar,et al. Medicinal plants and bioactive natural compounds in the treatment of non‐alcoholic fatty liver disease: A clinical review , 2017, Pharmacological research.
[13] Jing Fang,et al. Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier , 2017, Evidence-based complementary and alternative medicine : eCAM.
[14] Huanhuan Liu,et al. Genistein Ameliorates Fat Accumulation Through AMPK Activation in Fatty Acid-Induced BRL Cells. , 2017, Journal of food science.
[15] P. Tandon,et al. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease , 2017, Nutrients.
[16] Huanhuan Liu,et al. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[17] M. Doulberis,et al. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. , 2017, Metabolism: clinical and experimental.
[18] F. Bäckhed,et al. Altered Microbiota Contributes to Reduced Diet-Induced Obesity upon Cold Exposure , 2016, Cell metabolism.
[19] Lei He,et al. Perilla Oil Has Similar Protective Effects of Fish Oil on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Gut Dysbiosis , 2016, BioMed research international.
[20] D. Serra,et al. Mitochondrial fatty acid oxidation in obesity. , 2013, Antioxidants & redox signaling.
[21] E. Comelli,et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease , 2013, Hepatology.
[22] S. Park,et al. Doenjang, a fermented soybean paste, decreased visceral fat accumulation and adipocyte size in rats fed with high fat diet more effectively than nonfermented soybeans. , 2012, Journal of medicinal food.
[23] J. Suárez,et al. Reduction of body weight, liver steatosis and expression of stearoyl‐CoA desaturase 1 by the isoflavone daidzein in diet‐induced obesity , 2011, British journal of pharmacology.
[24] Mengwei Zang,et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. , 2011, Cell metabolism.
[25] Yuki Okabe,et al. Higher bioavailability of isoflavones after a single ingestion of aglycone-rich fermented soybeans compared with glucoside-rich non-fermented soybeans in Japanese postmenopausal women. , 2011, Journal of the science of food and agriculture.
[26] W. Mullin. Miso as a Functional Food , 2005 .
[27] E. Farnworth. Handbook of Fermented Functional Foods , 2003 .
[28] M. Kikuchi,et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. , 2000, The Journal of nutrition.
[29] K. Kaneko,et al. Effect of soybean varieties on the content and composition of isoflavone in rice-koji miso , 2007 .